DS 8500

Drug Profile

DS 8500

Alternative Names: DS-8500; DS-8500a

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 May 2017 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)
  • 01 May 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in USA, Japan (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top